Fidelity Advisor Biotechnology Fund Class A
FBTAX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- Fidelity Advisor Series VII MA United States of America
- IPO Date
- Dec 27, 2000
- CIK
- 0000315700
- Website
- fundresearch.fidelity.com
- Similar Companies
- Business
- Fidelity Advisor Biotechnology Fund Class A (FBTAX) is an open-end mutual fund managed by Fidelity Investments that seeks capital appreciation by investing primarily in common stocks of companies engaged in biotechnology and related life sciences activities, including research, development, manufacturing, and distribution of products and services such as biopharmaceuticals, diagnostics, drug delivery systems, and genomics technologies; the fund normally invests at least 80% of assets in securities of such companies, with exposure to both domestic and foreign issuers across mid- and large-cap blends. Top holdings as of recent reports include AbbVie Inc. (18.65%), Alnylam Pharmaceuticals Inc. (8.11%), Gilead Sciences Inc. (5.64%), argenx SE (4.65%), and Ascendis Pharma A/S (4.48%), representing approximately 41.53% of the portfolio, with sector allocation heavily weighted toward healthcare (93.75%), U.S. stocks (81.54%), and non-U.S. stocks (12.56%). The fund targets institutional and retail investors seeking sector-specific growth in the biotechnology industry, operates globally with primary focus on U.S. markets and exposure to Eurozone, Europe ex-Euro, Canada, and the United Kingdom, and maintains total net assets of approximately $1.74 billion across share classes, with Class A share class size at $728.91 million. Launched on December 27, 2000, and domiciled in the United States, the fund is headquartered at Fidelity Investments' facilities in Smithfield, Rhode Island. It features a net expense ratio of 0.96%, a front-end load of 5.75%, and is managed by Eirene Kontopoulos since July 15, 2018, with average fund management tenure reflecting over seven years on the fund. The fund benchmarks performance against the MSCI U.S. IMI Biotechnology 25/50 Index and S&P 500 Index, with recent quarterly reports highlighting strong gains driven by stock selection in core biotechnology amid clinical trial successes and product approvals, such as a key drug approval by the U.S. Food and Drug Administration in August 2024 after a delay. In the last 1-2 years, the fund has navigated sector volatility with notable performance, including Class I shares gaining 27.05% in Q3 2025 (outpacing the MSCI U.S. IMI Biotechnology 25/50 Index's 16.52% and S&P 500's 8.12%), attributed to overweight positions in outperformers like Alnylam Pharmaceuticals (+65%) and avoidance of underperformers like Moderna (-75%) through July 2025. Portfolio assets stood at $1,608.8 million as of September 30, 2025, with a turnover rate of 51%, reflecting active management amid biotech industry trends like gene therapies and autoimmune treatments, though no major acquisitions, partnerships, funding rounds, or structural reorganizations specific to the fund were reported. The fund continues to emphasize fundamental analysis of issuers' financial conditions and industry positions to capitalize on commercial launches and clinical advancements.